Phase 4 Completed N=69 Randomized Single-blind Treatment

Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block

ACL Surgery

Source: ClinicalTrials.gov NCT03401450 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2020

Primary outcomePrimary: Total Opioid Consumption Intraop Measured by Amounts of Morphine Equivalents — 23.21; 18.93 milligrams of morphine equivalents

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

This is a prospective, randomized, single blinded trial involving human subjects. The goal of this study is to determine an optimal location (proximal or distal) for the nerve block and whether it will make a difference in how much opioid the patient will receive during and after surgery. Ultrasound will identify the adductor canal and the proximal end of the adductor canal/apex of the femoral triangle to determine the location of the blocks. Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB proximal to true AC with bupivacaine 0.5% 20cc

Outcome Measures

Outcome	Result	p-value
PRIMARY Total Opioid Consumption Intraop Measured by Amounts of Morphine Equivalents	23.21; 18.93	—
PRIMARY Total Opioid Consumption Postop Measured by Amounts of Morphine Equivalents	10; 13.18	—
PRIMARY Side Effects Such as Nausea, Itching, Constipation.	0; 0	—
SECONDARY Motor Block (Muscle Weakness): in PACU and Measured in Surgeons' Clinic at 3, 6 and 12 Months.	—	—

Eligibility Criteria

Inclusion Criteria

Patients undergoing unilateral, ACL surgery with allograft.
Patients who consent to be randomized.
Patients must be English proficient.

Exclusion Criteria

Patients younger than 18 or older than 75 years of age;
Patients with a history of chronic pain or who are taking medications intended to treat chronic pain such as strong opioids;
Patients with history of neurologic disorder that can interfere with pain sensation;
Patients with a history of drug or alcohol abuse;
Patients who are unable to understand or follow instructions;
Patients with an allergy or a contraindication to any of the medications used in the study, or patients with a contraindication to any of the study procedures;
Patients with severe liver disease, renal insufficiency, congestive heart failure, and/ or significant heart disease;
Patients with a BMI over 42;
Any patient that the investigators feel cannot comply with all study related procedures.
Patients who do not tolerate Percocet.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03401450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.